Human IFN-γ T cell ELISPOT antibody pair - 20-plate

SKU
CT640-20
Validated ELISPOT antibody pair; reagents available separately (1920 determinations).
Format
20-plate
Price
€ 1,160
Reactivity
Human
Category
T cell ELISPOT
Analyte
IFN-γ
Description
Our ELISPOT antibody pairs are validated for high assay performance using the same reagents and materials included in U-CyTech ELISPOT kits. These antibody pairs are optimized for reliable and reproducible ELISPOT assays.
The antibody pairs are available in convenient 10-plate and 20-plate format, providing 960 or 1920 determinations, respectively.
Compatible reagents for ELISPOT assays can be purchased separately, allowing customization of your ELISPOT workflow.
Description
IFN-γ is a potent immune regulating cytokine that plays a central role in activating the body’s defense against infections and malignant cells. By enhancing antigen presentation and boosting the activity of T cells and natural killer (NK) cells, IFN-γ drives strong antiviral and anti tumor responses. It is primarily produced by activated T helper 1 (Th1) cells, cytotoxic T cells, γδ T cells, NK cells, and natural killer T (NKT) cells, making it a key indicator of cellular immune activation in research and diagnostic applications.
Alternative names
IFN-γ, IFN-gamma, IFN-g, IFNg, interferon γ, interferon-γ, interferon-gamma, interferon gamma, INF-g, INF-gamma, immune interferon, Type II interferon
Image

References

Authors, et al. Title Journal Year Volume Pages
Yun Qiao Efficacy and safety of PD-1 blockade-activated neoantigen specific cellular therapy for advanced relapsed non-small cell lung cancer Cancer Immunol Immunother 2025 74 60
Maaweya Awadalla Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination Front Immunol 2025 16 1526444
Anne Eugster Physiological and pathogenic T cell autoreactivity converge in type 1 diabetes Nat Commun 2024 15 9204
Jianting Long HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice Nat Commun 2024 15 2271
Jerry Mendell Gene therapy with bidridistrogene xeboparvovec for limb-girdle muscular dystrophy type 2E/R4: phase 1/2 trial results Nat Med 2024 30 199-206
Maureen Kleinhenz Toxin-neutralizing Abs are associated with improved T cell function following recovery from Staphylococcus aureus infection JCI Insight 2024 9 e173526
Marnix Foppen Intradermal Naked DNA Vaccination by DNA Tattooing for Mounting Tumor-Specific Immunity in Stage IV Melanoma Patients: A Phase I Clinical Trial Oncol Res Treat 2024 47 351-359
Yan Zhou A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomas BMC Med 2023 21 470
Karen Anthony T Cell Responses to Dystrophin in a Natural History Study of Duchenne Muscular Dystrophy Hum Gene Ther 2023 34 439-448
Aleixandra Rojas Alloreactive T cells to Assess Acute Rejection Risk in Kidney Transplant Recipients Transplant Direct 2023 9 e1478